Cerity Partners LLC Purchases Shares of 24,104 Verve Therapeutics, Inc. (NASDAQ:VERV)

Cerity Partners LLC purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 24,104 shares of the company's stock, valued at approximately $110,000.

A number of other large investors have also recently made changes to their positions in the stock. BVF Inc. IL grew its stake in shares of Verve Therapeutics by 962.2% in the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock worth $38,939,000 after buying an additional 6,254,050 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in shares of Verve Therapeutics by 57.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock worth $21,372,000 after buying an additional 1,382,176 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Verve Therapeutics by 18.5% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock worth $10,423,000 after buying an additional 288,678 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Verve Therapeutics by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company's stock worth $9,172,000 after buying an additional 25,093 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Verve Therapeutics in the 4th quarter valued at approximately $7,863,000. 97.11% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VERV. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Wall Street Zen upgraded Verve Therapeutics to a "hold" rating in a research report on Saturday, July 26th. Canaccord Genuity Group downgraded Verve Therapeutics from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $39.00 to $13.00 in a research report on Tuesday, June 17th. HC Wainwright downgraded Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 target price on the stock. in a research report on Wednesday, June 18th. Finally, Lifesci Capital cut Verve Therapeutics from a "strong-buy" rating to a "hold" rating and set a $12.00 target price for the company. in a research report on Wednesday, June 18th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $14.57.

Verve Therapeutics Price Performance

VERV stock remained flat at $11.13 during midday trading on Friday. The firm has a fifty day simple moving average of $9.30 and a two-hundred day simple moving average of $7.00. The firm has a market capitalization of $992.13 million, a price-to-earnings ratio of -5.27 and a beta of 2.23. Verve Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $11.40.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. The company had revenue of $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. As a group, research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.